Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361203 | 0.80 | NOTUM (0.44) | RAB9ANPC1NTSR1SMN1; SMN2KDM4E | |
| SCHEMBL4907831 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL4906175 | 0.68 | RAB9A (0.42) | RAB9ANPC1MEN1KMT2ARCE1 | |
| SCHEMBL94519 | 0.67 | MAPT (0.65) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13019480 | 0.67 | MAPT (0.65) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11988032 | 0.67 | MAPT (0.65) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14164175 | 0.65 | RAB9A (0.40) | RAB9ANPC1MEN1KMT2ARCE1 | |
| SCHEMBL20365744 | 0.63 | NPC1 (0.61) | RAB9ANPC1MEN1KMT2ARCE1 | |
| SCHEMBL308340 | 0.61 | — | — | |
| SCHEMBL10534630 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | CYP4X1, CYP4F3, CYP1A2 | RAB9A 1209/4885NPC1 731/4885MEN1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.